Case Report: Crizotinib is Effective in a Patient with ROS1-rearranged Pulmonary Inflammatory Myofibroblastic Tumor

Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal tumor that belongs to a subtype of soft tissue sarcoma, with a global prevalence of approximately 0.04% –0.7% [1]. IMT may occur at any age; however, it is more common among children and adolescents. The lungs are the most common site of IMT onset, although it may also occur at multiple sites such as the retroperitoneum, abdomen, and pelvic cavity. Surgery is the most important therapeutic approach for IMT because the tumor is insensitive to radiotherapy and chemotherapy; thus, the therapeutic options for patients with unresectable IMT are very limited [1].

Source: Lung Cancer - December 17, 2018 Category: Cancer & Oncology Authors: Shijie Mai, Gang Xiong, Dingwei Diao, Wenjing Wang, Yujie Zhou, Ruijun Cai Source Type: research